Cargando…
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
BACKGROUND: Studies on PD-L1 expression in breast cancer have gained importance in recent years, especially in triple-negative breast cancer (TNBC). Our aim was to analyze the differential expression of PD-L1 to explore its correlation with response to neoadjuvant chemotherapy (NACT) and patient sur...
Autores principales: | Oner, Gizem, Önder, Semen, Karatay, Hüseyin, Ak, Naziye, Tükenmez, Mustafa, Müslümanoğlu, Mahmut, İğci, Abdullah, Dincçağ, Ahmet, Özmen, Vahit, Aydiner, Adnan, Yavuz, Ekrem, Cabioğlu, Neslihan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414710/ https://www.ncbi.nlm.nih.gov/pubmed/34474671 http://dx.doi.org/10.1186/s12957-021-02361-9 |
Ejemplares similares
-
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
por: Oner, Gizem, et al.
Publicado: (2023) -
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
por: Cabioglu, Neslihan, et al.
Publicado: (2021) -
Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer
por: Cabioglu, Neslihan, et al.
Publicado: (2023) -
Favorable Outcome with Close Margins in Patients Undergoing Nipple/Skin Sparing Mastectomy with Immediate Breast Reconstruction: 5-year Follow-up
por: Özkurt, Enver, et al.
Publicado: (2018) -
High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)